Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-006893
Filing Date
2025-02-14
Accepted
2025-02-14 16:30:36
Documents
57
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 621762
2 ex10-2.htm EX-10.1 92594
3 ex31-1.htm EX-31.1 14348
4 ex31-2.htm EX-31.2 14331
5 ex32-1.htm EX-32.1 10824
  Complete submission text file 0001493152-25-006893.txt   3175102

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE aneb-20241231.xsd EX-101.SCH 23979
7 XBRL CALCULATION FILE aneb-20241231_cal.xml EX-101.CAL 32701
8 XBRL DEFINITION FILE aneb-20241231_def.xml EX-101.DEF 88373
9 XBRL LABEL FILE aneb-20241231_lab.xml EX-101.LAB 244175
10 XBRL PRESENTATION FILE aneb-20241231_pre.xml EX-101.PRE 200871
60 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 281218
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

EIN.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-40388 | Film No.: 25629676
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)